Article
Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression.
Cancer - 15 Sept 2001
Zhan M, Yu D, Lang A, Li L, Pollock R E
Abstract excerpt
BACKGROUND: p53 mutations occur in almost half of all soft tissue sarcomas (STS) and may contribute to multidrug resistance (MDR) in patients with STS. Doxorubicin (Dox) is one of the most active single agents in STS but is less effective in STS with p53 mutations. The effect of reintroducing wild type (wt) p53 into STS cells harboring p53 mutations on the cytotoxicity of DOX in vitro and in vivo was studied....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.